Renaissance Lakewood LLC - نتائج البحث

ماليزيا - الإنجليزية - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

spravato 28mg nasal spray

johnson & johnson sdn. bhd. - esketamine hydrochloride -

البرازيل - البرتغالية - ANVISA (Agência Nacional de Vigilância Sanitária)

spravato

janssen-cilag farmacÊutica ltda - cloridrato de escetamina - antidepressivos

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

lacrisert- hydroxypropyl cellulose insert

bausch & lomb incorporated - hydroxypropyl cellulose (1600000 wamw) (unii: rfw2et671p) (hydroxypropyl cellulose (1600000 wamw) - unii:rfw2et671p) - hydroxypropyl cellulose (type h) 5 mg - lacrisert is indicated in patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. lacrisert is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions. lacrisert is also indicated for patients with: lacrisert is contraindicated in patients who are hypersensitive to hydroxypropyl cellulose. clinical experience with lacrisert indicates that in some patients several weeks may be required before satisfactory improvement of symptoms is achieved. two applicators (one spare) are supplied with each package. preparing to insert lacrisert before opening the package of lacrisert, wash your hands thoroughly with soap and water. step 1: on a flat surface, open blister pocket slowly and smoothly by peeling back label area. each blister pocket contains one lacrisert ophthalmic insert. step 2: open applicator package with label side up. avoid touching grooved tip of the applicator. pick up applicator by the wide end and rinse the tip thoroughly under hot running tap water. gently shake off excess water. step 3: hold applicator with tip facing down and with forefinger on top to guide and apply gentle pressure. lightly press the grooved tip of the applicator onto the lacrisert ophthalmic insert and it will adhere to the applicator. it is important to follow steps 4 and 5 carefully or you might experience difficulty in keeping lacrisert (hydroxypropyl cellulose ophthalmic insert) in your eye. step 4: look into a mirror. starting with the right eye, turn your head to the right so that the colored part of the eye is close to your nose. use your free hand to grasp the lower lid between the thumb and index finger. pull the lid away from the eyeball and create a pocket between the white part of the eyeball and the lid. step 5: place the tip of the applicator containing lacrisert into the pocket. avoid touching the colored part of the eye. remove the applicator. it is important, after removing the applicator, to look down, then release the lower eyelid. lacrisert (hydroxypropyl cellulose ophthalmic insert) should remain deep in the lower pocket recess of the eye and not near the edge of the lower eyelid. repeat procedure with left eye, turning head to the left so that the colored part of the eye is close to your nose. rinse the applicator thoroughly under hot running tap water after use. gently shake off visible water droplets and promptly return it to the storage container. note that the storage container provides space for a strip of two lacrisert ophthalmic inserts next to the applicator storage compartment. important if lacrisert causes worsening of symptoms, or if new symptoms develop, it should be removed and your prescriber contacted. should the removal of the lacrisert ophthalmic insert be necessary, follow these instructions. caution: because this product may produce transient blurring of vision, you should exercise caution when operating hazardous machinery or driving a motor vehicle. store below 86°f (30°c) distributed by: bausch + lomb, a division of bausch health us, llc bridgewater, nj 08807 usa manufactured by: renaissance lakewood, llc, lakewood, nj 08701 usa this instructions for use has been approved by the u.s. food and drug administration. lacrisert is a trademark of bausch & lomb incorporated or its affiliates. © 2019 bausch & lomb incorporated or its affiliates 9421304 revised: 10/2019

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

subsys- fentanyl spray

west therapeutics development, llc - fentanyl (unii: uf599785jz) (fentanyl - unii:uf599785jz) - subsys is indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain. patients considered opioid tolerant are those who are taking for one week or longer, around-the-clock medicine consisting of at least 60 mg of oral morphine per day, at least 25 mcg of transdermal fentanyl per hour, at least 30 mg of oral oxycodone per day, at least 8 mg of oral hydromorphone per day, or at least 25 mg oral oxymorphone per day, or at least 60mg oral hydrocodone per day, or an equianalgesic dose of another opioid daily for a week or longer. patients must remain on around-the-clock opioids when taking subsys. limitations of use: - not for use in opioid non-tolerant patients. - not for use in the management of acute or postoperative pain, including headache/migraine, dental pain, or in the emergency room [see contraindications ( 4)]. - as part of the transmuc